Key result
Polymorphisms in LPL, LIPC, SCARB1, LCAT, CETP, RETN, MNSOD, and ADIPOQ linked to diabetic dyslipidemia.
Why the study?
Polymorphisms of genes encoding enzymes involved in lipoprotein metabolism play important roles in the development of diabetic dyslipidemia but their specific effects require investigation.
Are specific lipid metabolism enzyme-coding gene polymorphisms associated with diabetic dyslipidemia?
Case-Control (n=429)
Are specific lipid metabolism enzyme-coding gene polymorphisms associated with diabetic dyslipidemia?
p-value: p=<0.001
Several polymorphisms in lipid metabolism genes are significantly associated with diabetic dyslipidemia and may serve as predictive markers in high-risk patients.
Multiple lipid gene polymorphisms were associated with diabetic dyslipidemia; leaves open their value as predictive markers.
OBJECTIVE: The polymorphisms/mutations of genes encoding proteins and enzymes involved in lipoprotein metabolism play important roles in the development of diabetic dyslipidemia. The aim of our study was to investigate the effects of LPL (rs320), LIPC (rs2070895), SCARB1 (rs5888), LCAT (rs2292318), CETP (rs708272), ADIPOQ (rs1501299), RETN (rs3745367), PON1 (rs662), and MNSOD (rs4880) gene polymorphisms on lipid metabolism and diabetic dyslipidemia. METHODS: This case-control study included 217 patients with diabetic dyslipidemia and 212 healthy age- and gender-matched individuals. Genomic DNA isolation was performed from blood samples, and genotype analysis was performed using melting curve analysis on a LightCycler® 480 Instrument. The chi-square test was used to compare genotype distribution and allele frequencies between the groups. RESULTS: Significant associations were observed between LPL (rs320) (p<0.001), LIPC (rs2070895) (p<0.001), SCARB1 (rs5888) (p<0.001), LCAT (rs2292318) (p<0.001), CETP (rs708272) (p<0.001), ADIPOQ (rs1501299) (p=0.01), RETN (rs3745367) (p<0.001), and MNSOD (rs4880) (p<0.001) polymorphisms and diabetic dyslipidemia. However, no association was observed between PON1 (rs662) polymorphisms and diabetic dyslipidemia (p=0.611). CONCLUSION: LPL (rs320), LIPC (rs2070895), SCARB1 (rs5888), LCAT (rs2292318), CETP (rs708272), ADIPOQ (rs1501299), RETN (rs3745367), and MNSOD (rs4880) polymorphisms play an important role in basic molecular metabolism in diabetic dyslipidemia. Therefore, these polymorphisms may be used as a predictive marker for diabetic dyslipidemia in high-risk patients.
No takes yet. Share an insight, caveat, or question.
Meral Kayıkçıoğlu (2017) conducted a case-control in diabetic dyslipidemia (n=429). Polymorphisms of lipid metabolism enzyme-coding genes vs. Healthy controls was evaluated on Association between gene polymorphisms and diabetic dyslipidemia (p=<0.001). Polymorphisms in LPL, LIPC, SCARB1, LCAT, CETP, RETN, and MNSOD (all P<0.001) and ADIPOQ (P=0.01) were significantly associated with diabetic dyslipidemia, whereas PON1 was not.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: